普伐他汀对急性冠状动脉综合征患者血清高敏C-反应蛋白、白介素-6和内皮素-1水平的影响  

Effect of Pravastatin on Concentration of High Sensitive CRP,Interleukin-6 and Endothelin-1 in Patients with Acute Coronary Syndromes

作　　者：杨梅[1] 石礼[1] 

机构地区：[1]济南市第三人民医院急诊科,济南250101

出　　处：《中国医药导刊》2008年第9期1385-1386,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨普伐他汀对急性冠状动脉综合征(ACS)患者血清高敏C-反应蛋白(Hs-CRP)、白介素-6(IL-6)和内皮素-1(ET-1)水平变化的影响。方法:将ACS患者50例随机分为普伐他汀组25例和常规治疗组25例,分别于治疗前及治疗4周后行血清Hs-CRP、IL-6、ET-1检测,均采用放射免疫分析方法。另选同期健康体检的20例作为对照组。结果:ACS组治疗前血清Hs-CRP、IL-6、ET-1水平明显高于对照组(均P<0.01)。普伐他汀组治疗后血清Hs-CRP、IL-6、ET-1水平明显低于治疗前,但仍高于对照组(均P<0.05)。常规治疗组患者治疗后血清Hs-CRP、IL-6、ET-1降低不明显(P>0.05)。结论:Hs-CRP、IL-6、ET-1水平升高与ACS发病密切相关,普伐他汀可降低ACS患者血Hs-CRP、IL- 6、ET-1水平,具有减轻病变部位炎症反应和保护内皮的作用。Objective： To investigate the effect of pravastatin on changes in serum concentrations of Hs-CRP,IL-6 and Endothelin-l（ET-l） in patients with acute coronary syndromes（ACS）. Methods： 50 patients with ACS were randomly divided into pravastatin group（n=25）and reutine therapy group（n=25）. Serum Hs-CRP,IL-6 and ET-I was measured before and four weeks after file two treatment options respectively, Results： The level of Hs-CRP,IL-6 and ET-1 were higher than routine therapy group before therapy（P〈0.01）. The level of Hs-CRP,IL-6 and ET-I were decrcased significantly afler pravastatin therapy,and higher than concentrations（P〈0,01）. The concentrations of Hs-CRP,IL-6 and ET-1 changed only shghtly after the routine therapy （P〉0.05）.Conclusions： The level of Hs-CRP,IL-6 and ET-1 becoming higher in ACS patients may be related to tile pathogenesis of ACS. Pravastatin can reduce plasma level of Hs-CRP, IL-6 and ET-I contributing to treatment of ACS.

关 键 词：普伐他汀 高敏C-反应蛋白 自介素-6 内皮素-1 冠状动脉综合征 

分 类 号：R541.4[医药卫生—心血管疾病]